Healthcare

Nordic M&A’s healthcare unit is led by Fie Astrup, Dr. With, MBA. She is supported by senior advisor Jan Leschly and our scientific board, which consists of internationally leading experts within five major medical areas.

The combination of our medical background and our M&A skills means that we quickly understand the value and business models behind healthcare/life science companies. This gives us unique and rare skills in working with investors and partners in a transaction process.

Our dedicated focus is reputable and we have solved large and complex M&A processes within many medical areas:

SELECTED TRANSACTIONS

Financial advisor to the owners of Fischer Medical on the sale to AddLife

The Deal

Fischer Medical is a Danish company specialized in advanced surgery representing well – recognized suppliers from all over the world. The company has a leading market position in Denmark regarding medical instruments and implants for elective orthopedic surgery and non – invasive gynecology with long – lasting customer relationships to all leading hospitals and clinics.

Insight

AddLife is an independent and public listed European player in Life Science that offers high – quality products, services and consulting to both the private and public sectors. AddLife has about 1,800 employees in around 70 operating subsidiaries, which operate under their own brands with approximately SEK 7 billion in annual sales . With the acquisition of Fischer Medical , Addlife strengthens their presence within advanced surgery in the Nordics and opens up opportunities for co – operation with our other companies in Europe active in the same market segment. Since the beginning of the Covid – 19 pandemic, elective surgeries hav e been postponed which has created large backlogs in many countries. The refocusing within the Health care sector from covid – related treatments to elective surgery is indicating an increased demand for the offering from Fischer Medical in the years to come .

Financial advisor to Nordic Bioscience on the minority investment from KKR

The Deal

Nordic Bioscience has established a position as the world’s most experienced company within the extracellular matrix (ECM) through more than 25 years of dedicated research and development. The ECM is the non – cellular component of all tissues and organs and can be analyzed to identify new drug candidates in more than 50 disease areas, diagnose patients and evaluate the effect of existing drugs and drug candidates. Nordic Bioscience owns more than 150 patents and has published over 500 scientific papers in le ading scientific journals. The company has entered into partnerships with the world’s largest pharma companies to develop new drugs in four major disease areas (fibrosis, oncology, diabetes and cardiovascular) and has collaborations with leading diagnostic companies for the use of Nordic Bioscience’s biomarkers for diagnostic purposes. In addition, Nordic Bioscience services a growing international customer base of pharma, biotech and CROs with preclinical and clinical data analysis from its certified labor atory.

Insight

KKR is a leading global investment firm deeply committed to responsible investment, with a dedicated focus on health care growth and on partnering with leading companies and management teams to build and grow great businesses.

Financial advisor to the owners of Nordic Bioscience on the sale of Sanos Group to Investcorp

The Deal

Sanos is a global Contract Research Organization (“CRO”) specialized in osteoarthritis. Sanos is full – service CRO providing value – added services to pharma, biotech and research organizations to help plan and conduct clinical trials, a critical part in the development of new drugs and treatments. Sanos Group consists of a CRO specialized in osteoar thritis (“OA”) and a Site Management Organization (“SMO”) with a broader indication range focusing on lifestyle and age – related diseases. Sanos has built a worldwide reputation for its scientific expertise in osteoarthritis, its ability to recruit patients efficiently and a track record of executing safe and efficient clinical trials. The Sanos Group management will remain shareholders by investing alongside Investcorp.

Insight

In addition to the world – leading CRO business, Sanos Group consists of four sta te – of – the – art clinical research sites, including a brand – new phase I unit opened in Q4 2020. The Group is headquartered in Herlev (Copenhagen) with additional clinics located in Gandrup and Vejle, Denmark. In 2020 the company had a net turnover of DKK 149 m with an EBITDA of DKK 61 m. Investcorp has an established history of investing in the healthcare sector globally. The acquisition of Sanos is Investcorp’s 11th investment in the healthcare sector and its third in Europe.

Financial advisor to Daintel in the sale to Cambio Healthcare Systems

Financial advisor to DMDD on the sale to Synlab backed by Novo Holdings

Jan Leschly

Senior Advisor Jan Leschly is a well-known figure in the pharmaceutical industry. Jan was Chief Executive of SmithKline Beecham PLC (SB) from 1994 to 2000. Prior to joining SB, Jan was President and COO of Squibb Corporation and before that he was President of Novo Nordisk’s pharmaceutical unit. In 2000, Jan founded Care Capital and has been managing partner there ever since. Jan has a seat on the board of APM Holding. In his youth, Jan was a professional tennis player and in 1967 he was the tenth-best player on the world tennis circuit.

Healthcare

SELECTED TRANSACTIONS

The Deal

Insight

The Deal

Insight

The Deal

Insight

Head of Healthcare, Fie Astrup

Jan Leschly

Title 1

Title 2

Title 3

Title 4